S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Slow start to New York's legal pot market leaves farmers holding the bag
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Slow start to New York's legal pot market leaves farmers holding the bag
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Slow start to New York's legal pot market leaves farmers holding the bag
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Slow start to New York's legal pot market leaves farmers holding the bag
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:EQRX

EQRx (EQRX) Stock Forecast, Price & News

$1.83
+0.01 (+0.55%)
(As of 06/2/2023 ET)
Compare
Today's Range
$1.76
▼
$1.85
50-Day Range
$1.61
▼
$1.96
52-Week Range
$1.58
▼
$6.05
Volume
1.36 million shs
Average Volume
1.51 million shs
Market Capitalization
$891.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.57
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

EQRx MarketRank™ Forecast

Analyst Rating
Hold
1.67 Rating Score
Upside/​Downside
149.5% Upside
$4.57 Price Target
Short Interest
Bearish
7.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of EQRx in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.57) to ($0.66) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

523rd out of 983 stocks

Pharmaceutical Preparations Industry

252nd out of 486 stocks

See Top Rated MarketRank™ Stocks Here

EQRX stock logo

About EQRx (NASDAQ:EQRX) Stock

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Receive EQRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EQRx and its competitors with MarketBeat's FREE daily newsletter.

EQRX Stock News Headlines

June 2, 2023 | americanbankingnews.com
EQRx (NASDAQ:EQRX) Stock Price Up 3.6%
May 25, 2023 | americanbankingnews.com
EQRx (NASDAQ:EQRX) Trading Down 4.9%
June 4, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 19, 2023 | seekingalpha.com
CStone Breaks Up With Drugs Partner As U.S. Rollout Stalls
May 10, 2023 | msn.com
The World Has Its Way With EQRx
May 9, 2023 | finance.yahoo.com
Q1 2023 EQRx Inc Earnings Call
May 9, 2023 | markets.businessinsider.com
EQRx Announces Massive Strategic Reset, Slashes Pipeline & Workforce
May 8, 2023 | seekingalpha.com
EQRx, Inc. (EQRX) Q1 2023 Earnings Call Transcript
June 4, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 8, 2023 | msn.com
EQRx GAAP EPS of -$0.17 misses by $0.03
May 8, 2023 | finance.yahoo.com
EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results
May 8, 2023 | finance.yahoo.com
EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results
May 7, 2023 | americanbankingnews.com
EQRx (EQRX) Scheduled to Post Quarterly Earnings on Monday
May 5, 2023 | msn.com
Earnings Outlook For EQRx
April 27, 2023 | finance.yahoo.com
EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023
April 21, 2023 | technews.tmcnet.com
EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders
April 12, 2023 | americanbankingnews.com
EQRx (NASDAQ:EQRX) Trading Down 4.8%
April 5, 2023 | msn.com
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans
March 24, 2023 | americanbankingnews.com
EQRx (NASDAQ:EQRX) Stock Price Down 3.3%
March 13, 2023 | marketwatch.com
EQRx Chief Financial Officer Jami Rubin Resigns >EQRX
February 24, 2023 | bizjournals.com
Company founded to make 'radically' cheap drugs lays off 66
February 23, 2023 | finance.yahoo.com
EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
February 23, 2023 | msn.com
EQRx GAAP EPS of -$0.05 beats by $0.14
February 23, 2023 | finance.yahoo.com
EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
February 13, 2023 | msn.com
EQRx, Inc. (EQRX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
January 3, 2023 | finance.yahoo.com
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022 | insidermonkey.com
5 Best Affordable Stocks to Buy Under $5
See More Headlines

EQRX Price History

EQRX Company Calendar

Today
6/03/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EQRX
CUSIP
N/A
CIK
1843762
Web
iii.cmlifesciencesspac.com
Phone
617-315-2255
Fax
N/A
Employees
240
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.57
High Stock Price Forecast
$5.50
Low Stock Price Forecast
$3.20
Forecasted Upside/Downside
+149.5%
Consensus Rating
Hold
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-169,090,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-19.03%
Return on Assets
-17.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
22.63
Quick Ratio
22.63

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.70 per share
Price / Book
0.68

Miscellaneous

Outstanding Shares
487,360,000
Free Float
398,172,000
Market Cap
$891.87 million
Optionable
Optionable
Beta
0.57

Key Executives

  • Mr. Alexis A. Borisy A.M. (Age 51)
    Founder & Exec. Chairman of Board of Directors
    Comp: $858.22k
  • Ms. Melanie I. Nallicheri (Age 54)
    CEO & Director
    Comp: $832k
  • Ms. Jamilu E. Rubin (Age 59)
    Chief Financial Officer
    Comp: $479.57k
  • Dr. Eric E. Hedrick M.D. (Age 58)
    Chief Physician Exec.
    Comp: $575.1k
  • Mr. Robert Forrester LL.B. (Age 59)
    Co-Founder & Advisor
  • Dr. Peter B. Bach M.D. (Age 58)
    MAPP, Co-Founder & Advisor
  • Sir Andrew Dillon CBE
    Co-Founder & Advisor
  • Mr. Daniel Hoey (Age 56)
    Chief of Technical Operations
  • Ms. Dina Ciarimboli J.D. (Age 54)
    Gen. Counsel & Corp. Sec.
  • Ms. Rona Anhalt (Age 58)
    Chief People Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













EQRX Stock - Frequently Asked Questions

Should I buy or sell EQRx stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EQRx in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EQRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EQRX, but not buy additional shares or sell existing shares.
View EQRX analyst ratings or view top-rated stocks.

What is EQRx's stock price forecast for 2023?

3 equities research analysts have issued twelve-month price targets for EQRx's stock. Their EQRX share price forecasts range from $3.20 to $5.50. On average, they anticipate the company's share price to reach $4.57 in the next year. This suggests a possible upside of 149.5% from the stock's current price.
View analysts price targets for EQRX or view top-rated stocks among Wall Street analysts.

How have EQRX shares performed in 2023?

EQRx's stock was trading at $2.46 on January 1st, 2023. Since then, EQRX stock has decreased by 25.6% and is now trading at $1.83.
View the best growth stocks for 2023 here.

When is EQRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our EQRX earnings forecast.

What ETFs hold EQRx's stock?

ETFs with the largest weight of EQRx (NASDAQ:EQRX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and iShares Biotechnology ETF (IBB).

What is EQRx's stock symbol?

EQRx trades on the NASDAQ under the ticker symbol "EQRX."

Who are EQRx's major shareholders?

EQRx's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (5.05%), Softbank Group CORP. (4.44%), BlackRock Inc. (3.28%), State Street Corp (2.90%), Arboretum Ventures LLC (2.85%) and Geode Capital Management LLC (0.90%).

How do I buy shares of EQRx?

Shares of EQRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is EQRx's stock price today?

One share of EQRX stock can currently be purchased for approximately $1.83.

How much money does EQRx make?

EQRx (NASDAQ:EQRX) has a market capitalization of $891.87 million. The company earns $-169,090,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

How many employees does EQRx have?

The company employs 240 workers across the globe.

How can I contact EQRx?

EQRx's mailing address is 667 MADISON AVENUE, NEW YORK NY, 10065. The official website for the company is iii.cmlifesciencesspac.com. The company can be reached via phone at 617-315-2255 or via email at investors@eqrx.com.

This page (NASDAQ:EQRX) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -